Cargando…

Resolvin E1's Antimicrobial Potential Against Aggregatibacter Actinomycetemcomitans

BACKGROUND: Microorganisms along with host response play a key role in the development of periodontal and peri-implant infections. Advanced periodontal and peri-implant diseases are most likely associated with bacterial plaques that trigger host immune response and eventually lead to the destruction...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdullatif, Fahad A., Almaarik, Basmah, Al-Askar, Mansour
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9095612/
https://www.ncbi.nlm.nih.gov/pubmed/35571980
http://dx.doi.org/10.3389/froh.2022.875047
_version_ 1784705794140274688
author Abdullatif, Fahad A.
Almaarik, Basmah
Al-Askar, Mansour
author_facet Abdullatif, Fahad A.
Almaarik, Basmah
Al-Askar, Mansour
author_sort Abdullatif, Fahad A.
collection PubMed
description BACKGROUND: Microorganisms along with host response play a key role in the development of periodontal and peri-implant infections. Advanced periodontal and peri-implant diseases are most likely associated with bacterial plaques that trigger host immune response and eventually lead to the destruction of the attachment apparatus and bone loss around a tooth or a dental implant. A recent systematic review and meta-analysis revealed that Aggregatibacter actinomycetemcomitans had the highest association with peri-implantitis. Resolvin E1 (RvE1) is part of the specialized pro-resolving lipid mediator family biosynthesized from omega-3, polyunsaturated fatty acids (PUFAs), and eicosapentaenoic acid (EPA). Although RvE1 is an established anti-inflammatory agent, it was found that its application as a treatment or as a preventive drug had an indirect effect on the subgingival microbiota of both rats and rabbits with experimental periodontitis. AIM: The aim of this study is to evaluate the direct antimicrobial effect of RvE1 on Aggregatibacter actinomycetemcomitans bacteria. MATERIALS AND METHODS: The study comprised three groups that underwent minimum inhibitory concentration (MIC) against Aggregatibacter actinomycetemcomitans. The first group was tested with the RvE1 working concentration of 5 ug/ml, the second group was tested with ethanol (EtOH), 10% as the working concentration, and the final group was diluted in phosphate-buffered saline (PBS) as the positive control. Optical density (OD(600)) was used for the comparison of bacterial growth among the tested groups. The experiment was conducted in three biological replicates. Data were analyzed using SPSS, and results were analyzed by using one-way analysis of variance (ANOVA) followed by post-hoc Bonferroni using a minimum level of significance (P-value) of 0.05. RESULTS: Minimum inhibitory concentration was 1.25 μg/ml and 5% for RvE1 and EtOH, respectively. RvE1's mean optical density (OD(600)) was 0.156 ± 0.021 and was significantly lower compared with all the other groups (P-value < 0.01). The EtOH group (mean OD(600) 0.178 ± 0.013) and the PBS group (mean OD(600) 0.1855 ± 0.022) did not reveal a significant difference (P-value = 0.185). CONCLUSION: RvE1 demonstrated significant antimicrobial activity against A. actinomycetemcomitans with an MIC of 1.25 μg/ml. The RvE1 group showed significantly lower bacterial growth compared to the EtOH and PBS groups.
format Online
Article
Text
id pubmed-9095612
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-90956122022-05-13 Resolvin E1's Antimicrobial Potential Against Aggregatibacter Actinomycetemcomitans Abdullatif, Fahad A. Almaarik, Basmah Al-Askar, Mansour Front Oral Health Oral Health BACKGROUND: Microorganisms along with host response play a key role in the development of periodontal and peri-implant infections. Advanced periodontal and peri-implant diseases are most likely associated with bacterial plaques that trigger host immune response and eventually lead to the destruction of the attachment apparatus and bone loss around a tooth or a dental implant. A recent systematic review and meta-analysis revealed that Aggregatibacter actinomycetemcomitans had the highest association with peri-implantitis. Resolvin E1 (RvE1) is part of the specialized pro-resolving lipid mediator family biosynthesized from omega-3, polyunsaturated fatty acids (PUFAs), and eicosapentaenoic acid (EPA). Although RvE1 is an established anti-inflammatory agent, it was found that its application as a treatment or as a preventive drug had an indirect effect on the subgingival microbiota of both rats and rabbits with experimental periodontitis. AIM: The aim of this study is to evaluate the direct antimicrobial effect of RvE1 on Aggregatibacter actinomycetemcomitans bacteria. MATERIALS AND METHODS: The study comprised three groups that underwent minimum inhibitory concentration (MIC) against Aggregatibacter actinomycetemcomitans. The first group was tested with the RvE1 working concentration of 5 ug/ml, the second group was tested with ethanol (EtOH), 10% as the working concentration, and the final group was diluted in phosphate-buffered saline (PBS) as the positive control. Optical density (OD(600)) was used for the comparison of bacterial growth among the tested groups. The experiment was conducted in three biological replicates. Data were analyzed using SPSS, and results were analyzed by using one-way analysis of variance (ANOVA) followed by post-hoc Bonferroni using a minimum level of significance (P-value) of 0.05. RESULTS: Minimum inhibitory concentration was 1.25 μg/ml and 5% for RvE1 and EtOH, respectively. RvE1's mean optical density (OD(600)) was 0.156 ± 0.021 and was significantly lower compared with all the other groups (P-value < 0.01). The EtOH group (mean OD(600) 0.178 ± 0.013) and the PBS group (mean OD(600) 0.1855 ± 0.022) did not reveal a significant difference (P-value = 0.185). CONCLUSION: RvE1 demonstrated significant antimicrobial activity against A. actinomycetemcomitans with an MIC of 1.25 μg/ml. The RvE1 group showed significantly lower bacterial growth compared to the EtOH and PBS groups. Frontiers Media S.A. 2022-04-27 /pmc/articles/PMC9095612/ /pubmed/35571980 http://dx.doi.org/10.3389/froh.2022.875047 Text en Copyright © 2022 Abdullatif, Almaarik and Al-Askar. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oral Health
Abdullatif, Fahad A.
Almaarik, Basmah
Al-Askar, Mansour
Resolvin E1's Antimicrobial Potential Against Aggregatibacter Actinomycetemcomitans
title Resolvin E1's Antimicrobial Potential Against Aggregatibacter Actinomycetemcomitans
title_full Resolvin E1's Antimicrobial Potential Against Aggregatibacter Actinomycetemcomitans
title_fullStr Resolvin E1's Antimicrobial Potential Against Aggregatibacter Actinomycetemcomitans
title_full_unstemmed Resolvin E1's Antimicrobial Potential Against Aggregatibacter Actinomycetemcomitans
title_short Resolvin E1's Antimicrobial Potential Against Aggregatibacter Actinomycetemcomitans
title_sort resolvin e1's antimicrobial potential against aggregatibacter actinomycetemcomitans
topic Oral Health
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9095612/
https://www.ncbi.nlm.nih.gov/pubmed/35571980
http://dx.doi.org/10.3389/froh.2022.875047
work_keys_str_mv AT abdullatiffahada resolvine1santimicrobialpotentialagainstaggregatibacteractinomycetemcomitans
AT almaarikbasmah resolvine1santimicrobialpotentialagainstaggregatibacteractinomycetemcomitans
AT alaskarmansour resolvine1santimicrobialpotentialagainstaggregatibacteractinomycetemcomitans